Theodore E. Hebert

Array ( [id] => 13402357 [patent_doc_number] => 20180252721 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-06 [patent_title] => SELECTION OF PATIENTS FOR COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 15/756898 [patent_app_country] => US [patent_app_date] => 2016-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21447 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15756898 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11472786 [patent_doc_number] => 20170059569 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-03-02 [patent_title] => 'METHODS AND COMPOSITIONS FOR CYTOMETRIC DETECTION OF CIRCULATING TUMOR CELL MARKERS IN A SAMPLE' [patent_app_type] => utility [patent_app_number] => 15/236278 [patent_app_country] => US [patent_app_date] => 2016-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10059 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15236278 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13311509 [patent_doc_number] => 20180207291 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => ANTI-TUMOUR IMMUNE RESPONSES TO MODIFIED SELF-EPITOPES [patent_app_type] => utility [patent_app_number] => 15/746077 [patent_app_country] => US [patent_app_date] => 2016-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15952 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15746077 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14537405 [patent_doc_number] => 20190204324 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => ANTIGENIC COMPOSITION FOR DETECTING AUTO-ANTIBODY WITH SPECIFIC RESPONSE TO EXOSOMAL PROTEIN EIF3A, AND METHOD FOR DIAGNOSING LIVER CANCER USING ANTIGENIC COMPOSITION [patent_app_type] => utility [patent_app_number] => 15/743471 [patent_app_country] => US [patent_app_date] => 2016-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12295 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15743471 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11106283 [patent_doc_number] => 20160303253 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-20 [patent_title] => 'ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER' [patent_app_type] => utility [patent_app_number] => 15/196586 [patent_app_country] => US [patent_app_date] => 2016-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 66061 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15196586 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11749304 [patent_doc_number] => 09707302 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-07-18 [patent_title] => 'Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer' [patent_app_type] => utility [patent_app_number] => 15/190805 [patent_app_country] => US [patent_app_date] => 2016-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 33 [patent_no_of_words] => 65268 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15190805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12862327 [patent_doc_number] => 20180179283 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-28 [patent_title] => T CELL RECEPTOR LIKE ANTIBODIES HAVING FINE SPECIFICITY [patent_app_type] => utility [patent_app_number] => 15/579974 [patent_app_country] => US [patent_app_date] => 2016-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37354 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15579974 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11362905 [patent_doc_number] => 20170000885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-05 [patent_title] => 'METHODS OF TREATING CANCER USING ANTI-OX40 ANTIBODIES AND PD-1 AXIS BINDING ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 15/176106 [patent_app_country] => US [patent_app_date] => 2016-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 97164 [patent_no_of_claims] => 81 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15176106 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11090754 [patent_doc_number] => 20160287722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-06 [patent_title] => 'Immunoconjugates with an Intracellularly-Cleavable Linkage' [patent_app_type] => utility [patent_app_number] => 15/174304 [patent_app_country] => US [patent_app_date] => 2016-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11366 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15174304 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13300807 [patent_doc_number] => 20180201940 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-19 [patent_title] => THERAPEUTIC VACCINE FOR TREATING OR PREVENTING MERKEL CELL POLYOMA VIRUS-ASSOCIATED TUMORS [patent_app_type] => utility [patent_app_number] => 15/579233 [patent_app_country] => US [patent_app_date] => 2016-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16331 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15579233 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12999981 [patent_doc_number] => 10023648 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-07-17 [patent_title] => Anti-TOSO chimeric antigen receptor and its use [patent_app_type] => utility [patent_app_number] => 15/166306 [patent_app_country] => US [patent_app_date] => 2016-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 3 [patent_no_of_words] => 7414 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15166306 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11311726 [patent_doc_number] => 20160347836 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-12-01 [patent_title] => 'TREATMENT OF HODGKIN\'S LYMPHOMA USING AN ANTI-PD-1 ANTIBODY' [patent_app_type] => utility [patent_app_number] => 15/164960 [patent_app_country] => US [patent_app_date] => 2016-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 18013 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15164960 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11059599 [patent_doc_number] => 20160256562 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-08 [patent_title] => 'ANTIBODY-SN-38 IMMUNOCONJUGATES WITH A CL2A LINKER' [patent_app_type] => utility [patent_app_number] => 15/161806 [patent_app_country] => US [patent_app_date] => 2016-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 62311 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15161806 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11129286 [patent_doc_number] => 20160326262 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-10 [patent_title] => 'COMBINATION THERAPIES COMPRISING ANTI-ERBB3 AGENTS' [patent_app_type] => utility [patent_app_number] => 15/160523 [patent_app_country] => US [patent_app_date] => 2016-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 39 [patent_no_of_words] => 13626 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15160523 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11400463 [patent_doc_number] => 20170021002 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-26 [patent_title] => 'AUGMENTATION OF CANCER AND CANCER ENDOTHELIAL VACCINE IMMUNOGENICITY BY HISTONE DEACETYLASE INHIBITORS' [patent_app_type] => utility [patent_app_number] => 15/158476 [patent_app_country] => US [patent_app_date] => 2016-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 2927 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15158476 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11066254 [patent_doc_number] => 20160263218 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-15 [patent_title] => 'BYSTANDER IMMUNE SUPPRESSION AS A PREDICTOR FOR RESPONSE TO A VACCINE' [patent_app_type] => utility [patent_app_number] => 15/154648 [patent_app_country] => US [patent_app_date] => 2016-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 7883 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15154648 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11541719 [patent_doc_number] => 20170095545 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-06 [patent_title] => 'INHIBITION OF TUMOR ANGIOGENESIS BY CHECKPOINT INHIBITORS AND ACTIVE VACCINATION' [patent_app_type] => utility [patent_app_number] => 15/149130 [patent_app_country] => US [patent_app_date] => 2016-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 5579 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15149130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11422771 [patent_doc_number] => 20170030915 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-02 [patent_title] => 'ISOLATION AND DETECTION OF CANCER CELLS' [patent_app_type] => utility [patent_app_number] => 15/147528 [patent_app_country] => US [patent_app_date] => 2016-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 11383 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15147528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11106281 [patent_doc_number] => 20160303252 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-20 [patent_title] => 'CALICHEAMICIN DERIVATIVE-CARRIER CONJUGATES' [patent_app_type] => utility [patent_app_number] => 15/145238 [patent_app_country] => US [patent_app_date] => 2016-05-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 28991 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15145238 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11120516 [patent_doc_number] => 20160317490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-11-03 [patent_title] => 'Taxane- and Taxoid-Protein Compositions' [patent_app_type] => utility [patent_app_number] => 15/143968 [patent_app_country] => US [patent_app_date] => 2016-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 6243 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15143968 [rel_patent_id] =>[rel_patent_doc_number] =>)